Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial: Erratum.
- DOI
- 10.1097/ju.0000000000005265
- Published
- 2026 Dec
- Container
- The Journal of urology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/ju.0000000000005265,
title = {Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial: Erratum.},
author = {Zhang S and Li T and Li D and Yin Y and Zhu W and Jiang N and Zhang S and Yang R and Guo H},
year = {2026},
journal = {The Journal of urology},
doi = {10.1097/ju.0000000000005265},
url = {https://doi.org/10.1097/ju.0000000000005265}
}RIS
TY - JOUR TI - Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial: Erratum. AU - Zhang S AU - Li T AU - Li D AU - Yin Y AU - Zhu W AU - Jiang N AU - Zhang S AU - Yang R AU - Guo H PY - 2026 JO - The Journal of urology DO - 10.1097/ju.0000000000005265 UR - https://doi.org/10.1097/ju.0000000000005265 ER -
APA
S, Z., T, L., D, L., Y, Y., W, Z., N, J., S, Z., R, Y., & H, G. (2026). Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial: Erratum.. The Journal of urology. https://doi.org/10.1097/ju.0000000000005265
Source records
- pubmed · retrieved 2026-11-10T19:09:51.799Z